Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 17, 2026 07:00 ET | Source: Gyre Therapeutics Inc.

Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment

Gyre Therapeutics’ Hydronidone Granted Priority Review Designation in China for CHB-Associated Liver Fibrosis